At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 567 enrolled
Drug / intervention
Pegilodecakin +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
In Brief
A Phase 3 clinical trial evaluating Pegilodecakin and FOLFOX for Pancreatic Cancer. Completed, enrolled 567 participants across 130 sites in 13 countries.
Detailed Summary
To compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX alone in participants with metastatic pancreatic cancer as measured by overall survival.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesAustralia, Austria, Belgium, Canada, France, Germany, Italy, Poland, South Korea, Spain, Taiwan, United Kingdom, United States
CollaboratorsARMO BioSciences
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartMar 2017
Primary CompletionSep 2019
Study CompletionMar 2020
TodayJul 2026
First PostedOct 5, 2016
Enrollment StartMar 1, 2017
Primary CompletionSep 9, 2019
Study CompletionMar 5, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.7 years ago
Interventions
Pegilodecakinbiological
Pegilodecakin plus FOLFOX
FOLFOXdrug
FOLFOX Alone